NLRP3 and cryopyrin-associated periodic syndrome: These agents have been proven to be effective in the treatment of Cryopyrin-associated periodic syndromes (CAPS) caused by NLRP3 gene mutations and have also been applied in clinical trials for other NLRP3-associated disorders (Dinarello et al., 2012; Dinarello and van der Meer, 2013).